Arrowhead Pharmaceuticals, Inc.
0HI3.L
London Stock Exchange85.86
USD
-0.99
- -
Arrowhead Pharmaceuticals, Inc.
0HI3.L
(London Stock Exchange)
Recent
price
85.86
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops RNA interference (RNAi)-based therapeutics to treat intractable diseases across multiple areas including cardiometabolic, pulmonary, liver, neuromuscular, central nervous system, and complement mediated diseases; its proprietary Targeted RNAi Molecule (TRiM) platform enables tissue-agnostic gene silencing for targets previously considered undruggable, with key pipeline candidates such as plozasiran (ARO-APOC3) for familial chylomicronemia syndrome and severe hypertriglyceridemia, zodasiran (ARO-ANG3) for severe hypertriglyceridemia, ARO-HBV for hepatitis B, ARO-AAT for alpha-1 antitrypsin deficiency-associated lung and liver disease, and others targeting cardiovascular, pulmonary fibrosis, MASH, and rare neuromuscular disorders. Founded in 1989 and headquartered in Pasadena, California, the company operates primarily in the United States with a manufacturing facility in Verona, Wisconsin, and advances wholly owned and partnered programs aimed at patients with significant unmet needs in genetic and chronic diseases. Recent developments include a November 2024 global license and collaboration agreement with Sarepta Therapeutics providing $500 million in upfront cash and $325 million in equity investment plus up to $3.4 billion in milestones for multiple clinical and preclinical programs in rare diseases, a $200 million milestone payment earned from Sarepta in November 2025, a September 2025 global license deal with Novartis for up to $2 billion in milestones on a Parkinson's disease program, extension of cash runway into 2028 supporting potential launches like plozasiran pending FDA approval in 2025, and a shift toward commercial-stage focus in cardiometabolic therapies.